Evidence map›Paper›PMID 36762874›Full record

ArticleNano letters2023

Bone-Targeting Exosome Mimetics Engineered by Bioorthogonal Surface Functionalization for Bone Tissue Engineering.

Chung-Sung Lee, Jiabing Fan, Hee Sook Hwang, Soyon Kim, Chen Chen, Minjee Kang, Tara Aghaloo, Aaron W James, Min Lee

Open access · greenAbstract read
In one paragraph

Article in Nano letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chung-Sung LeeDivision of Advanced Prosthodontics, University of California, Los Angeles, California 90095, United States.ORCID 0000-0002-4996-042X
Jiabing FanDivision of Advanced Prosthodontics, University of California, Los Angeles, California 90095, United States.
Hee Sook HwangDivision of Advanced Prosthodontics, University of California, Los Angeles, California 90095, United States.
Soyon KimDivision of Advanced Prosthodontics, University of California, Los Angeles, California 90095, United States.ORCID 0000-0003-1030-8482
Chen ChenDivision of Advanced Prosthodontics, University of California, Los Angeles, California 90095, United States.
Minjee KangDivision of Advanced Prosthodontics, University of California, Los Angeles, California 90095, United States.
Tara AghalooDivision of Diagnostic and Surgical Sciences, School of Dentistry, University of California, Los Angeles, California 90095, United States.
Aaron W JamesDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, United States.
Min LeeDivision of Advanced Prosthodontics, University of California, Los Angeles, California 90095, United States.ORCID 0000-0003-2813-2091
University of California, Los Angeles · USJohns Hopkins University · US

Funding

Tribbles homolog 3 and BMP-2 induced bone formationR01DE027332 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tara L Aghaloo, Min Lee · 2018 to 2026
$2.7M
Hydrogel delivery of DBM and exosome mimetics for bone repairR01DE031711 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Min Lee · 2022 to 2026
$1.8M
NIDCR NIH HHS R01 DE027332NIDCR NIH HHS R01 DE031711
6 · The paper itself

Abstract

Extracellular vesicles have received a great interest as safe biocarriers in biomedical engineering. There is a need to develop more efficient delivery strategies to improve localized therapeutic efficacy and minimize off-target adverse effects. Here, exosome mimetics (EMs) are reported for bone targeting involving the introduction of hydroxyapatite-binding moieties through bioorthogonal functionalization. Bone-binding ability of the engineered EMs is verified with hydroxyapatite-coated scaffolds and an ex vivo bone-binding assay. The EM-bound construct provided a biocompatible substrate for cell adhesion, proliferation, and osteogenic differentiation. Particularly, the incorporation of Smoothened agonist (SAG) into EMs greatly increased the osteogenic capacity through the activation of hedgehog signaling. Furthermore, the scaffold integrated with EM/SAG significantly improved in vivo reossification. Lastly, biodistribution studies confirmed the accumulation of systemically administered EMs in bone tissue. This facile engineering strategy could be a versatile tool to promote bone regeneration, offering a promising nanomedicine approach to the sophisticated treatment of bone diseases.

Indexed as

ExosomesTissue EngineeringBone and BonesCell DifferentiationHedgehog ProteinsHydroxyapatitesOsteogenesisTissue DistributionTissue ScaffoldsHedgehog ProteinsHydroxyapatitesbioorthogonal engineeringbone targetingclick chemistrydrug deliveryExosome mimetics

Identifiers

PMID36762874
PMCPMC10106420
OpenAlexW4319826294

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.